Comparable stake leader
WELLS FARGO & COMPANY/MN
SEC ownership of LUMOS PHARMA, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001126234.
Disclosed value leader
WELLS FARGO & COMPANY/MN
Comparable rows
1/2
Latest evidence
30 Sep 2024
- Parsed ownership sources
-
13D/G and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
WELLS FARGO & COMPANY/MN
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
1 of 2
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
WELLS FARGO & COMPANY/MN
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Sep 2024
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001126234
- Issuer location
- Austin, TX
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of LUMOS PHARMA, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
WELLS FARGO & COMPANY/MN
Disclosed value leader
WELLS FARGO & COMPANY/MN
Comparable rows
1/2
Latest evidence
30 Sep 2024
13D/G
3/4/5
Lead comparable stake: 0.8%
1 rows are not safely comparable across share classes.
13D/G row: WELLS FARGO & COMPANY/MN
Quick read
WELLS FARGO & COMPANY/MN leads the comparable SEC ownership view at 0.8%.
1 of 2 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens WELLS FARGO & COMPANY/MN's linked filing trail.
Comparable ownership
Top 1
WELLS FARGO & COMPANY/MN
0.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-2 of 2 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| WELLS FARGO & COMPANY/MN |
13D/G
Wells Fargo & Company
|
0.8%
|
$251,476
64,981 shares
|
$0 | 30 Sep 2024 |
| David B. Karpf |
3/4/5
Chief Medical Officer
|
—
mixed-class rows
|
$26,582
20,294 shares
mixed-class rows
|
— | 01 Feb 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 16 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-13 of 13 reporting-owner rows connected to LUMOS PHARMA, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
13
Largest Forms 3/4/5 holder
David B. Karpf
Net 12M change
$0
Latest report
12 Dec 2024
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| David B. Karpf | Chief Medical Officer | $26,582 | Mixed | 01 Feb 2023 | ||
| Bradley J. Powers | General Counsel | $0 | Mixed | 12 Dec 2024 | ||
| Lota S. Zoth | Director | $0 | Mixed | 12 Dec 2024 | ||
| John C. McKew | Chief Scientific Officer | $0 | Mixed | 12 Dec 2024 | ||
| Richard J. Hawkins | Chief Executive Officer, Director | $0 | Mixed | 12 Dec 2024 | ||
| Chad Allen Johnson | Director | $0 | Mixed | 12 Dec 2024 | ||
| Kevin M. Lalande | Director | $0 | Mixed | 12 Dec 2024 | ||
| Joseph S. McCracken | Director | $0 | Mixed | 12 Dec 2024 | ||
| Aaron Schuchart | Chief Business Officer | $0 | Mixed | 12 Dec 2024 | ||
| Lori D. Lawley | Chief Financial Officer | $0 | Mixed | 12 Dec 2024 | ||
| An van Es-Johansson | Director | $0 | Mixed | 12 Dec 2024 | ||
| Thomas A. Raffin | Director | $0 | Mixed | 12 Dec 2024 | ||
| Pisit Duke Pitukcheewanont | Chief Medical Officer | $0 | Mixed | 12 Dec 2024 |
Recent insider transactions for LUMOS PHARMA, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.